Medscape

Neurologic Side Effects Rare but Often Severe With Immune Checkpoint Inhibitors

A retrospective study highlights the potential for encephalitis and other serious neurologic side effects over the course of ...

BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...
The American Journal of Managed Care

Data Highlights Factors Impacting Immune Checkpoint Inhibitors in mCRC

MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...

Immune Checkpoint Inhibitors Market Report 2026-2030 with Detailed Company Profiles, Grant Analyses, Partnership Evaluations and More

The immune checkpoint inhibitors market presents opportunities in next-gen therapies targeting new immune checkpoints, boosting treatment efficacy, especially for difficult-to-treat cancers. Growth is ...
Healio

Checkpoint inhibition can be ‘like pouring lighter fluid onto the fire’ of inflammation

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Inflammatory arthritis as a result of immune checkpoint cancer therapy remains a pressing ...
The Cardiology Advisor

AACR: Myocarditis in First Month of Immune Checkpoint Inhibitor Therapy Predictive of Fatality

Patients who develop myocarditis within the first month of receiving immune checkpoint inhibitor therapy are more likely to have MC fatality.
GEN

Immune Checkpoint Inhibitor Extends Tumor Residence Time for Cancer Therapy

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with ...
Cure Today

Immune Checkpoint Inhibitors For Cancer Associated With Psoriasis Risk

A nationwide cohort study in Taiwan found a higher risk of psoriasis in cancer patients treated with immune checkpoint inhibitors compared to other therapies. The study analyzed data from 3,188 ...
Medscape

Checkpoint Inhibitor Prices Dropped Marginally Over Decade

A recent study found that monthly prices of checkpoint inhibitors decreased only slightly from 2015 to 2024, with declines in annual average sales prices ranging from 0.21% to 4.85%. "Prices of ...

Turning immune cells into tumor allies: A cancer cell protein can reprogram frontline defenders

Cancer cells can disarm the immune system not just by hiding from it, but by actively reprogramming nearby immune cells into a suppressed state. This previously unrecognized molecular interaction, ...